Summary
The plasma kinetics of 5,6-dihydro-5-azacytidine (DHAC) was determined in mice using an HPLC method following an intravenous dose of 2000 mg/kg (LD10). Pharmacokinetic parameters calculated from these single dose data were sufficient to predict steady state plasma concentrations produced by s.c. infusion of DHAC. Lethal toxicity (LD66) occurred at an infusion rate of 37 mg/kg/h (111mg/m2/h), corresponding to a plasma steady-state DHAC concentration 38 ± 14 μg/ml when the infusion time was 96 h; no lethality occurred at infusion times of 72 h or less.
In vitro clonogenic assays and in vivo therapeutic experiments with L1210 tumor indicated that increasing the exposure time at concentrations near 25 μg/ml from 24 to 72 h increased the cell kill only slightly. The maximum log cell kill of L1210 estimated from either in vitro or in vivo data was 1.5 logs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zaharko DS, Covey JM: Effects of 5-aza-2′-deoxycytidine on L1210 bearing mice in combination with the biochemical modulator thymidine or the immune modulator pyran copolymer. Cancer Treat Rep, 68:1255–1264
Covey JM, Zaharko DS: Comparison of the in vitro cytotoxicity of 5-aza-2′-deoxycytidine (L1210) with its thera- peutic and toxic effect in mice. Europ J Cancer, in press, 1984
Beisler JA, Abassi MM, Kelley JA, Driscoll JS: Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine. J Med Chem 20:806–812, 1977
Voytek P, Beisler JA, Abassi MM, Wolpert-DeFilippes MK: Comparative studies of the cytostatic action and metabolism of 5-azacytidine and 5,6-dihydro-5-azacytidine. Cancer Res 37:1956–1961, 1977
Presant CA, Coulter D, Valeriote F, Vietti TJ: Contrasting, cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice. JNCI 66:1151–1154, 1981
Investigational Drug Branch: Annual Report to the Food and Drug Administration, Dihydro-5-azacytidine hydrochloride NSC 264880 IND 19762, National Cancer Institute, Bethesda Jan. 1983, pp. 2–3
Curt GA, Kelley JA, Fine RL, Huguenin PN, Jenkins J, Batist G, Roth JS, Collins J: A Phase I and pharmacokinetic study of dihydro-azacytidine (DHAC; NSC 264880). (Abstract) Proc ASCO 3:37, 1984
Huguenin PN, Jayaram HN, Kelley JA: Reverse phase HPLC determination of 5,6-dihydro-5-azacytidine in biological fluids. J Liquid Chromatogr 7:1433–1453, 1984
Theeuwes F, Yum SI: Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid formulations. Ann Biomed Eng 4:343–353, 1976
Skipper HE, Schabel FM, Wilcox WS: Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Treat Rep 35:1–111, 1964
Gibaldi M, Perrier D: Pharmacokinetics, Vol. I. Swarbrick, JS (ed), Marcel Dekker, Inc., New York, 1975, pp 68–69
Schabel FM: Test systems for evaluating the antitumor activity of nucleoside analogues. In: RT Walker, E DeClarc, F Eckstein (eds.): Nucleoside analogues. Plenum Publishing Corp., 1979, pp 363–394
Momparler RL, Gonzales FA: Effect of intravenous infusion of 5-aza-2′-deoxycytidine on survival time of mice with L1210 leukemia. Cancer Res 38:2673–2678, 1978
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zaharko, D.S., Covey, J.M. & Kelley, J.A. Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor. Invest New Drugs 3, 35–41 (1985). https://doi.org/10.1007/BF00176822
Issue Date:
DOI: https://doi.org/10.1007/BF00176822